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The R403Q mutation in β-myosin heavy chain was the first mutation to be identified as
responsible for familial hypertrophic cardiomyopathy (FHC). In spite of extensive work on
the functional sequelae of thismutation, themechanism bywhich themutant protein causes the
disease has not been definitely identified. Here we directly compare contraction and relaxation
mechanics of single myofibrils from left ventricular samples of one patient carrying the R403Q
mutation to those from a healthy control heart. Tension generation and relaxation following
sudden increase anddecrease in [Ca2+]weremuch faster in theR403Qmyofibrilswith relaxation
rates being the most affected parameters. The results show that the R403Qmutation leads to an
apparent gain of protein function but a greater energetic cost of tension generation. Increased
energy cost of tension generation may be central to the FHC disease process, help explain some
unresolved clinical observations, and carry significant therapeutic implications.
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The R403Q mutation in the β-myosin heavy chain
was the first mutation to be identified as responsible
for familial hypertrophic cardiomyopathy (FHC)
(Geisterfer-Lowrance et al. 1990), a primary disease of the
cardiac sarcomere that is the most commonly identified
cause of cardiac sudden death in young people. The
functional sequelae of the R403Q mutation have been
extensively investigated using a variety of experimental
models and approaches (Cuda et al. 1993; Lankford
et al. 1995; Sata & Ikebe, 1996; Geisterfer-Lowrance
et al. 1996; Marian et al. 1999; Tyska et al. 2000; Lowey,
2002; Keller et al. 2004) but the cardiac sarcomeres of
affected individuals have never been directly examined.
Here we compare contraction and relaxation of left
ventricular myofibrils from one patient carrying the
R403Q mutation to those from a healthy control heart.
To investigate sarcomere mechanics we use previously
This paper has online supplemental material.
published techniques to measure and control the force
and length of single myofibrils activated and relaxed by
fast solution switching (Tesi et al. 2002; Piroddi et al.
2007). One advantage of this approach was that we
could probe the acto-myosin transduction cycle while
keeping the native structured sarcomere environment of
the mutant protein. Preliminary report of this work has
been published in abstract form (Belus et al. 2007).
Methods
Patients
The investigation conforms with the principles outlined
in the Declaration of Helsinki and had been approved by
the local Ethics Committee. Informed consent was given
for bothmutational analysis andmechanical experiments.
A 24-year-old man, with a severe family history of
premature cardiac death, diagnosed at 13 with FHC, and
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now with progressive worsening of dyspnoea on effort
was referred to our institution (see online Supplemental
file and figure). Mutational analysis of the myofilament
protein-encoding genes associated with FHC identified a
missenseR403Qmutation in the gene coding forβ-myosin
heavy chain (MYH7). As the patient showed significant
resting outflow obstruction (peak gradient estimated at
rest by continuous wave Doppler was 85mmHg), he
underwent extended surgical myectomy. Small samples
from the myectomy were used for myofibril isolation.
Control myofibrils were obtained from samples of
the left side of the interventricular septum of a female
healthy donor (24 years) heart that had not been trans-
planted for technical reasons. Both R403Q and control
samples were transported in cold cardioplegic solution
and, on arrival in the laboratory, immediately frozen in
liquid nitrogen, stored at −80◦C, then used for myofibril
isolation within the following few weeks. Previously
reported data (Piroddi et al. 2007) from myofibrils of
non-failing, non-hypertrophic left ventricular samples of
patients undergoing corrective cardiac surgery could also
be used as controls.
Myofibril preparation and apparatus
Ventricular specimens were cut into thin strips under a
stereomicroscope in ice-cold rigor solution containing
(mM):NaCl 132, KCl 5,MgCl2 1, Tris 10, EGTA5 (pH 7.1).
The strips were incubated for 3 h in the same solutionwith
added 1% Triton-X 100. Triton was then removed and the
stripswerehomogenized in rigor solution toproducemyo-
fibril suspensions.
In the present experiments we used previously
published techniques (Tesi et al. 2002; Piroddi et al. 2007).
Briefly, a small volume of the myofibril suspension was
transferred to a temperature-controlled chamber (15◦C)
filled with relaxing solution (pCa 8.0) and mounted
on an inverted microscope. Selected preparations
(single myofibrils or bundles of few myofibrils, 25–80μm
long, 1–4μm wide) were mounted horizontally between
two glass microtools. One tool was connected to a
length-control motor that could produce rapid (< 1ms)
length changes. The second tool was a calibrated
cantilevered force probe (2–6 nm nN−1; frequency
response 2–5 kHz). Force was measured from the
deflection of the image of the force probe projected on a
split photodiode. Average sarcomere length and myofibril
diameter were measured from video images (ca 1800×).
The initial sarcomere length of the preparations was
set around 2.2μm. Myofibrils were activated and relaxed
by rapidly translating the interface between two flowing
streams of different pCa solutions across the length of the
preparation. The solution change took place with a time
constant of 2–3ms and was complete in less than 5ms.
Activating and relaxing solutions, calculated as
previously described (Tesi et al. 2002), were at pH 7.00
and contained 10mM total EGTA (CaEGTA/EGTA ratio
set to obtain pCa 8.0 and 4.5), 5 mM MgATP, 1mM free
Mg2+, 10 mM Mops, propionate and sulphate to adjust
the final solution to an ionic strength of 200mM and
monovalent cation concentration of 155mM. Creatine
phosphate (CP; 10mM) and creatine kinase (200 unit
ml−1) were added to all solutions. Contaminant inorganic
phosphate (Pi) from spontaneous breakdown of MgATP
and CP was reduced to less than 5μM by a Pi scavenging
system (purine-nucleoside-phosphorylase with substrate
7-methyl-guanosine) (Tesi et al. 2002). All solutions to
which the samples andmyofibrils were exposed contained
a cocktail of protease inhibitors including leupeptin
(10μM), pepstatin (5μM), PMSF (200μM) and E64
(10μM), as well as NaN3 (500μM) and DTE (2mM).
Results
Figure 1 shows, for both control donor and R403Q
myofibrils, representative traces of tension responses
to maximal Ca2+ activation by fast solution switching;
averagedata for bothmyofibril groups are shown inTable 1
together with data previously reported for myofibrils
taken from left ventricular samples of control (non-failing,
non-hypertrophic) patients (Piroddi et al. 2007).
Control data from the age-matched donor heart were
undistinguishable from the previously reported controls;
as shown by Piroddi et al. (2007), in spite of some
variability, myofibril mechanical and kinetic parameters
did not differ significantly among myofibril populations
taken from different control samples.
In the R403Q myofibrils, maximal isometric tension
(P0) was lower (P < 0.01 versus control patients) or
tended to be lower (P < 0.1 versus control donor)
whereas kinetics of tension development (kACT, as well
as kTR), were markedly faster compared to both control
groups (Table 1 and Fig. 1B), indicative of faster cross-
bridge turnover rate. In all myofibril populations, the
time course of Ca2+-activated tension development was
mono-exponential; the activation rate constant (kACT)was
the same as kTR. The latter is the rate constant of tension
redevelopment following large mechanical perturbations,
applied to the myofibril during steady Ca2+ activation,
aimed at detaching most of force-generating crossbridges
(Brenner, 1988). The similarity between kACT and kTR
shows that kACT is not limited by the rate with which
thin filaments are switched on by Ca2+, but rather reflects
isometric crossbridge turnover rates (i.e. the sum of the
apparent rates with which crossbridges enter and leave
their force-generating states).
Active tension fully relaxed with step reduction of
[Ca2+] below the contraction threshold (Fig. 1A). The
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kinetics of tension relaxation in control donor and
R403Q myofibrils are shown on a faster time scale in
Fig. 1C. As previously described (Piroddi et al. 2007),
the time course of force relaxation in human cardiac
myofibrils was biphasic, starting with a slow, seemingly
linear, force decay followed, after a ‘shoulder’, by a fast,
exponential, relaxation phase. It has been shown (Poggesi
et al. 2005) that the slow linear force decay occurs while
sarcomeres are isometric and its rate constant (slow
kREL) is predominantly the apparent rate with which
attached crossbridges leave force-generating states; the fast
exponential phase follows the ‘give’ of a few sarcomeres
and is dominated by intersarcomere dynamics. Relaxation
kinetics were much faster in the R403Qmyofibrils than in
Figure 1. Tension generation and relaxation in control donor and R403Q heart myofibrils
A, representative tension responses (top traces) of donor and R403Q myofibrils maximally activated and fully
relaxed by fast solution switching (pCa changes at arrows as indicated). Temperature 15◦C. Fast length changes
(bottom traces) are applied to the myofibrils under conditions of steady tension generation. kACT is the rate
constant of tension generation following fast Ca2+ activation; kTR is the rate constant of tension redevelopment
following the release–restretch. B, the time course of tension activation following sudden [Ca2+] increase of the
donor and R403Q myofibrils shown in A are superimposed on a faster time base after normalization for maximal
tension. C, tension relaxation kinetics following sudden Ca2+ removal; same traces as in A superimposed on
a faster time base after normalization for maximal tension. The rate constant of the early slow force decline
(slow kREL) is estimated from the slope of the regression line fitted to the tension trace normalized to the entire
amplitude of the tension relaxation transient. The rate constant for the final fast phase of tension decline (fast kREL)
is estimated from mono-exponential fit. D, mean values of slow kREL for the donor (open columns) and R403Q
(filled columns) myofibrils. Bars above columns are S.E.M.; the number of myofibrils is given above S.E.M. bars.
the control myofibrils (Table 1 and Fig. 1C and D). The
rate constant of the fast relaxation phase (fast kREL) was
1.5 to 2 times faster in the R403Q myofibrils compared
to controls. The isometric, linear, relaxation phase was
shorter (ca 25%) and its rate constant (slow kREL) was
more than 3 times faster in the R403Q myofibrils than
in both control groups, indicative of faster crossbridge
detachment under isometric conditions.
Discussion
The results provide evidence that the apparent rate
with which force-generating crossbridges detach under
isometric conditions as well as the overall crossbridge
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Table 1. Means (± S.E.M.) of resting parameters, maximum active tension (P0), and kinetic data for
full tension generation and relaxation in R403Q and control myofibrils
R403Q Control donor Control patients1
Resting conditions
Sarcomere length (μm) 2.23 ± 0.05 (13) 2.21 ± 0.02 (22) 2.19 ± 0.01 (62)
Passive tension (mN mm−2) 9.4 ± 1.9 (16) 9.9 ± 1.5 (19) 10.1 ± 1.1 (53)
Active tension generation
P0 (mN mm−2) 60 ± 7§ (16) 92 ± 12 (19) 108 ± 7 (53)
kACT (s−1) 1.40 ± 0.15∗§ (18) 0.84 ± 0.06 (22) 0.73 ± 0.03 (62)
kTR (s−1) 1.37 ± 0.16∗§ (18) 0.77 ± 0.04 (22) 0.68 ± 0.03 (55)
Full tension relaxation
Slow phase duration (ms) 169 ± 10∗§ (16) 225 ± 10 (22) 226 ± 8 (47)
Slow kREL (s−1) 0.60 ± 0.05∗§ (16) 0.17 ± 0.02 (22) 0.15 ± 0.02 (47)
Fast kREL (s−1) 5.12 ± 0.34∗§ (16) 2.91 ± 0.16 (22) 2.90 ± 0.16 (47)
1Data from Piroddi et al. (2007), pooled from 4 patients. ∗P < 0.01 R403Q versus control donor,
§P < 0.01 R403Q versus control patients (estimated by Student s t test; number of myofibrils in
parentheses). Experimental conditions: 15◦C; pCa of relaxing and activating solutions, 8.00 and 4.50,
respectively; [MgATP] 5 mM; [Pi] < 5 μM.
turnover are markedly accelerated in the R403Q
preparations. In the absence of inorganic phosphate (Pi),
as in the present experiments, crossbridges leave their
force-generating states through transitions that lead to
Figure 2. Reaction pathway for acto-myosin ATPase and energy transduction cycle
A, in this generally accepted scheme (Gordon et al. 2000), nucleotide occupancy of the myosin (M) active site
modifies myosin s binding affinity for actin (A), defining two general categories of crossbridges: ‘strong binding
states’ (AM, AM.ADP) and ‘weak binding states’ (AM.ATP, AM.ADP.Pi); crossbridges in strong states may generate
force; crossbridges in weak states do not and are mostly detached forms (M.ATP, M.ATP.Pi). The release of
inorganic phosphate (Pi) is thought to power the working stroke. It is well established that crossbridge transitions
involved in Pi release and force generation are reversible and, in the presence of Pi, both forward (ADP release
and ATP binding) and backward (Pi rebinding and reversal of the power stroke) transitions of crossbridges from
force-generating to non-force-generating states occur. However, myofibril slow kREL, measured in the absence of
Pi, only probes forward detachment transitions that lead to ATP hydrolysis steps. B, 2-state crossbridge scheme.
AMno force represents all weak binding states (mostly detached) and AMforce all strong binding states. The transition
from the non-force-generating states to the force-generating states has an apparent rate constant f app whereas
gapp describes the return to the non-force-generating states by means of ADP release and ATP binding. The
apparent rate constant for the reverse transition f ′app that depends on [Pi] can be neglected under the conditions
of the present study.
ATP hydrolysis steps (Gordon et al. 2000; Poggesi et al.
2005) (Fig. 2A) and the faster crossbridge detachment
rate associated with the R403Q mutation will generate
higher energy costs to produce a given tension (higher
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ATPase/tension ratio) (de Tombe & Stienen, 2007). The
increase in slow kREL observed in R403Q sarcomeres
implies that the increase in crossbridge detachment
rates is the major factor responsible for the faster
isometric crossbridge turnover (faster kACT and kTR)
and the lower maximal isometric tension. According
to a simple 2-state model of acto-myosin interactions
(Brenner, 1988) (Fig. 2B) in which the formation of
force-generating crossbridges occurs via an apparent rate
constant f app, whereas crossbridge detachment occurs
with apparent rate constant g app, the overall cross-
bridge turnover rate is given by f app + g app, tension is
proportional to f app/(f app + g app), and the energy cost of
tension generation (ATPase/tension ratio) is proportional
to g app (Brenner, 1988; de Tombe & Stienen, 2007). Given
slow kREL ≈ g app (0.17± 0.02 s−1 and 0.60± 0.05 s−1 in
control donor and R403Q myofibrils, respectively) and
kTR ≈ f app + g app (0.77± 0.04 s−1 and 1.37± 0.16 s−1 in
control donor and R403Q myofibrils, respectively), the
increase in g app associated with the R403Q mutation
accounts almost entirely for the changes in P0 and kTR (as
well as kACT) observed in these experiments and predicts a
3-fold increase in the energy cost of tension generation in
R403Q sarcomeres. Though only direct measurements of
ATPase activity can definitely confirm this conclusion, the
results strongly support the idea that the R403Qmutation
leads to inefficient ATP utilization for tension generation.
Inefficient ATP utilization for tension generation may
lead to an energetic defect that results in cardio-
myocyte dysfunction and hypertrophy (Crilley et al. 2003;
Ashrafian et al. 2003). If myocardial wall tension and
energy demand are not uniformly distributed in the left
ventricle as suggested by theoretical models (DeAnda
et al. 1998) and experimental studies (Dunn, 1984),
extra energy requirements could be more damaging in
specific myocardial regions providing an explanation for
the asymmetrical hypertrophy and degenerative changes
observed in the interventricular septum of the patient (see
Supplemental file).
The present experiments focus on the functional
properties of cardiac myofilaments independent of
disease-associated secondary changes occurring in other
cell functions and sarcomere ionicmicroenvironment. It is
more certain therefore that the faster kinetics observed in
the R403Q myofibrils are due to the functional properties
of the mutant protein. Kinetic parameters of the R403Q
myofibrils were the fastest human ventricular parameters
ever measured in our laboratory. In contrast, tension
activation and relaxation kinetics were slower or tended
to be slower in myofibrils from secondary hypertrophic
and failing human hearts (authors unpublished results),
evidence that present results do not reflect myofilament
changes secondary to the disease (myofilament Ca2+
sensitivity as well as sarcomeric protein composition of
the R403Q myofibrils are under investigation on leftover
tissue of the patient sample). Whereas initial functional
studies had suggested that the R403Q mutation depresses
acto-myosin interaction kinetics and contractile function
potentially leading to a hypertrophic compensatory
response (Cuda et al. 1993; Lankford et al. 1995; Sata &
Ikebe, 1996), more recent work seemed to imply that the
mutant myosin has enhanced motor activity (Tyska et al.
2000; Lowey, 2002; Keller et al. 2004). Interestingly, pure
mutant myosin isolated from the heart of a patient with
homozygous R403W mutation showed a 2-fold increase
in actin-activated ATPase activity and the Km for actin
indicating both a large enhancement of the enzymatic
properties and a lower affinity for actin (Keller et al.
2004). Our mechanical observations agree well with these
biochemical findings.
Our finding that relaxation kinetics are faster in the
R403Q myofibrils than in the controls is apparently
inconsistent with clinical evidence of diastolic dysfunction
associated with FHC (Ho et al. 2002). In the whole
heart, however, multiple mechanisms determine the time
course of tension relaxation. For example, the extensive
fibrosis foundathistological examinationof themyectomy
samples (see Supplemental Fig. 1D) may contribute to the
clinically observed impairment in ventricular relaxation.
Moreover, in intact cardiac myocytes the mechanisms
related to myoplasmic [Ca2+] reduction are important
determinants of the time course of tension relaxation.
With fast solution switching on myofibrils we focus solely
on the sarcomeric determinants of the relaxation process
and, under our present experimental conditions (absence
of Pi, Fig. 2), we only probe one specific pathway through
which crossbridges leave force-generating states (Gordon
et al. 2000; Poggesi et al. 2005). In the intact myocardium,
compromised energetics may slow down relaxation by
altering the ionic environment of contractile proteins
and/or the Ca2+ transport function needed for myo-
plasmic [Ca2+] to fall. Elevated myoplasmic [Ca2+] and
altered function of other ion transporters needed for
normal electrophysiological activity may also render the
myocardium vulnerable to the arrhythmias that underlie
sudden cardiac death in FHC.
Present results on human cardiac myofibrils add
substantial support to the hypothesis that inefficient
utilization of ATP, hence compromised energetics, plays
a central role in HCM. 31P NMR spectroscopy studies in
transgenic mouse (Spindler et al. 1998; Javadpour et al.
2003) and human hearts (Crilley et al. 2003) bearing
FHC-associated mutations in sarcomeric proteins found
a large fall in phosphocreatine concentration ([PCr]) but
unchanged ATP levels. The [PCr] fall was also present
in R403Q transgenic mouse hearts without hypertrophy
(Spindler et al. 1998) and in asymptomatic FHC patients
(Crilley et al. 2003), implying that the energetic defect
was associated with the mutant sarcomeric proteins, not
to left ventricular hypertrophy per se. Finally, FHC-like
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phenotypes have been found with mutations in a variety
ofmetabolic genes and in AMP-dependent protein kinase,
an enzyme regulating substrate selection for ATP synthesis
in muscle (Ashrafian et al. 2003; Crilley et al. 2003). These
provide further support for defective energetics as being
pivotal in understanding FHC disease.
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